[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-379228-105":59,"doc-detail-379228-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-current-landscape-of-m6a-modification-in-urological-cancers","The current landscape of m6A modification in urological cancers","","N6-methyladenosine (m6A) methylation is a reversible, dynamic epigenetic RNA modification implicated in tumorigenesis, growth, and progression of urological cancers. This review summarizes the links between m6A modification and renal cell carcinoma, bladder cancer, and prostate cancer, and highlights the biological functions of m6A regulators in tumor cells. It also discusses underlying mechanisms and evaluates future use as biomarkers or therapeutic targets to benefit patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-current-landscape-of-m6a-modification-in-urological-cancers/379228/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-current-landscape-of-m6a-modification-in-urological-cancers/379228.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is m6A modification and why is it important in urological cancers?","Question",{"text":113,"@type":114},"m6A methylation is a dynamic, reversible epigenetic modification of RNA. It is increasingly recognized as being involved in the tumorigenesis, development, and progression of urological tumors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which urological cancers are discussed in the review?",{"text":118,"@type":114},"The review focuses on renal cell carcinoma, bladder cancer, and prostate cancer, summarizing how m6A modification relates to each.",{"name":120,"@type":111,"acceptedAnswer":121},"How do m6A regulators contribute to tumor cell behavior?",{"text":122,"@type":114},"The review explains that m6A is controlled by writers, erasers, and readers. These regulators mediate methylation, demethylation, and downstream recognition, thereby influencing m6A levels and affecting cell phenotype and cancer-related processes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},379228,1790451624,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":26},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Submitted 11 April 2023  \nAccepted 11 August 2023 Published 7 September 2023  \nCorresponding author Cai Lv, [lvcai815@163.com](lvcai815@163.com)  \nAcademic editor Srinivas Sistla  \nAdditional Information and Declarations can be found on page 14  \nDOI 10.7717/peerj.16023  \n Copyright 2023 Zeng et al.  \nDistributed under  \nCreative Commons CC-BY 4.0  \nOPEN ACCESS  \nThe current landscape of m6A modification in urological cancers  \nYaohui Zeng, Cai Lv, Bangbei Wan and Binghao Gong  \nDepartment of Urology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China  \nABSTRACT  \nN6-methyladenosine (m6A) methylation is a dynamic and reversible procession of epigenetic modifications. It is increasingly recognized that m6A modification has been involved in the tumorigenesis, development, and progression of urological tumors. Emerging research explored the role of m6A modification in urological cancer. In this review, we will summarize the relationship between m6A modification, renal cell carcinoma, bladder cancer, and prostate cancer, and discover the biological function of m6A regulators in tumor cells. We will also discuss the possible mechanism and future application value used as a potential biomarker or therapeutic target to benefit patients with urological cancers.  \nSubjects Genetics, Oncology, Urology  \nKeywords N6-methyladenosine, Renal cell carcinoma, Bladder cancer, Prostate cancer, Epigenetic modifications, Urological cancer  \nINTRODUCTION  \nMore and more studies have shown that epigenetic modifications play an important role in the occurrence and development of a variety of tumors. Many scholars and experts focus on epigenetic modifications to develop potential future approaches for cancer therapies now. There are various carriers to reflect epigenetic information, such as DNA methylation, noncoding RNAs, and histone modifications (Cavalli & Heard, 2019) . RNA modification is the one of important modification methods which can influence the cell phenotype. It has been demonstrated that RNA modification was associated with embryonic development, cardiovascular diseases ( Wu et al., 2021b), mitochondrial diseases, neurological disorders (Suzuki, 2021), and human cancer (Barbieri & Kouzarides, 2020; Song et al., 2021), especially human cancer. To this day, it is reported that over 300 types of post-transcriptional modifications could be found in cells (Boccaletto et al., 2022), such as N1-methyladenosine, 5-methylcytosine, N6-methyladenosine (m6A), N7-methylguanosine, RNA cap methylations, pseudouridine (Barbieri & Kouzarides, 2020) . It was validated that the most commonly occurring post-transcriptional modifications in eukaryotic cell was m6A (Dubin & Taylor, 1975; Roundtree et al., 2017) .  \nM6A was found in mRNA in 1974 and was considered to be associated with the selective processing of mRNA sequences (Desrosiers, Friderici & Rottman, 1974) . The distribution of m6A modification was determined in 2012 (Dominissini et al., 2012) . M6A modification is a reversible process and has been found in mRNA, miRNA, lncRNA, and circRNA (Ma et al., 2019). The m6A peaks were mainly found in the location near the 50 untranslated region  \nHow to cite this article Zeng Y, Lv C, Wan B, Gong B. 2023. The current landscape of m6A modification in urological cancers. PeerJ 11:e16023 [http://doi.org/10.7717/peerj.16023](http://doi.org/10.7717/peerj.16023)  \n(UTR), 30 UTR, transcription starting site region (TSS), coding sequence (CDS), and the stop codon (Dominissini et al., 2012; Chen et al., 2020c; Gan et al., 2021). It is modulated by kinds of m6A RNA methylation regulators. Writers, a kind of methyltransferases, mediate the methylation and upregulate the level of RNA modification (Zaccara, Ries & Jaffrey, 2019) . Methyltransferase-like 3 (METTL3), Methyltransferase-like 14 (METTL14), and Wilms tumor 1-associated protein (WTAP) are the three most important writers to form the WMM (WTAP, METTL3 and METTL14) ","cbCail0SbL98ORMA","https://ap.wps.com/l/cbCail0SbL98ORMA","pdf",1019487,24,"English","# Abstract\n# Introduction\n## Epigenetic modifications in cancer\n## Overview of m6A modification and distribution\n## m6A regulators: writers, erasers, readers\n## Biological processes regulated by m6A\n## Clinical and therapeutic potential in urological cancers","[{\"question\":\"What is m6A modification and why is it important in urological cancers?\",\"answer\":\"m6A methylation is a dynamic, reversible epigenetic modification of RNA. It is increasingly recognized as being involved in the tumorigenesis, development, and progression of urological tumors.\"},{\"question\":\"Which urological cancers are discussed in the review?\",\"answer\":\"The review focuses on renal cell carcinoma, bladder cancer, and prostate cancer, summarizing how m6A modification relates to each.\"},{\"question\":\"How do m6A regulators contribute to tumor cell behavior?\",\"answer\":\"The review explains that m6A is controlled by writers, erasers, and readers. These regulators mediate methylation, demethylation, and downstream recognition, thereby influencing m6A levels and affecting cell phenotype and cancer-related processes.\"}]","The current landscape of m6A modification in urological cancers | PDF",1790234674]